Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes
NCT03526250 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 13, 2018
- Completion date
- September 30, 2024
- Enrollment
- 23 (actual)
- Sites
- 117
Conditions
As the registry lists them; a condition with its own page is linked.
advanced malignant solid neoplasm, recurrent childhood ependymoma, recurrent ewing sarcoma, recurrent glioma, recurrent hepatoblastoma, recurrent kidney wilms tumor, recurrent langerhans cell histiocytosis, recurrent malignant germ cell tumor, recurrent malignant glioma, recurrent medulloblastoma, recurrent neuroblastoma, recurrent non-hodgkin lymphoma, recurrent osteosarcoma, recurrent peripheral primitive neuroectodermal tumor, recurrent rhabdoid tumor, recurrent rhabdomyosarcoma, recurrent soft tissue sarcoma, refractory ependymoma, refractory ewing sarcoma, refractory glioma, refractory hepatoblastoma, refractory langerhans cell histiocytosis, refractory malignant germ cell tumor, refractory malignant glioma, refractory medulloblastoma, refractory neuroblastoma, refractory non-hodgkin lymphoma, refractory osteosarcoma, refractory peripheral primitive neuroectodermal tumor, refractory rhabdoid tumor, refractory rhabdomyosarcoma, refractory soft tissue sarcoma